Azurity Pharmaceuticals v. Annora Pharma: FIRVANQ® Vancomycin Patent Dispute Stayed
Azurity Pharmaceuticals filed suit against Annora Pharma in the District of New Jersey asserting 7 U.S. patents protecting FIRVANQ® vancomycin hydrochloride oral solution. The case was resolved by a consent stay order after 188 days — a resolution that typically signals parallel proceedings or settlement negotiations are underway.
Seven-patent ANDA battle over FIRVANQ® lands in procedural hold
On 28 August 2024, Azurity Pharmaceuticals, Inc. filed an infringement action against Annora Pharma Private, Ltd. in the U.S. District Court for the District of New Jersey (Case No. 2:24-cv-08809). The complaint asserted seven U.S. patents — US11638692B2, US10959947B2, US10959949B2, US10493028B2, US10959946B2, US10959948B2, and US10688046B2 — all relating to FIRVANQ®, Azurity’s branded vancomycin hydrochloride oral solution used to treat Clostridioides difficile infections.
The case closed on 4 March 2025 when plaintiff’s counsel transmitted a proposed Consent Order Staying Proceedings to the presiding judges — the Honorable Susan D. Wigenton and Magistrate Judge Jose R. Almonte. A stay by consent order means both parties agreed to pause active litigation, and the court accepted that request. This outcome does not constitute a merits ruling and leaves the underlying patent claims unresolved at the district court level.
The 188-day duration before the stay is consistent with the pattern seen in Hatch-Waxman ANDA litigation, where defendants often file inter partes review (IPR) petitions at the USPTO, prompting the parties to request a stay pending PTAB resolution. The consent nature of the stay suggests Annora Pharma did not oppose the hold — which may indicate ongoing settlement discussions, a pending IPR petition, or both. The public record does not disclose the specific trigger for the stay or its expected duration.
Filing to Case Stayed in 188 days
188 days to stay — consistent with ANDA litigation timelines where parallel PTAB or settlement talks prompt early procedural holds
Case stayed by consent: what the procedural hold means for both parties
A consent stay suspends — not ends — the litigation
A consent order staying proceedings means both parties jointly asked the court to pause the case, and the court agreed. Unlike a dismissal, a stay preserves the litigation in its current state: all claims remain live, no merits findings are made, and the court retains jurisdiction. The case can resume if either party moves to lift the stay or a triggering condition — such as a PTAB final written decision — is satisfied.
No merits ruling issuedAzurity’s patents remain asserted and enforceable
For Azurity Pharmaceuticals, the stay preserves all seven asserted patents in an active but paused enforcement posture. FIRVANQ® market exclusivity is not directly affected by the stay itself. However, if the stay was triggered by an IPR petition challenging one or more of these patents, Azurity faces validity scrutiny at the PTAB. A stay also delays any potential injunctive relief that would block Annora’s generic from launching.
Patents remain assertedAnnora avoids immediate injunction risk while parallel tracks proceed
For Annora Pharma, the stay suspends the district court proceedings without requiring any admission of infringement or validity. If Annora filed IPR petitions — a common ANDA defendant strategy — the stay allows PTAB proceedings to potentially narrow or eliminate the patent claims before costly district court discovery. The consent to the stay suggests Annora viewed the procedural pause as commercially acceptable.
No infringement findingGeneric vancomycin entry remains unresolved — sector watches PTAB
The stayed litigation means the timeline for Annora’s potential generic vancomycin HCl oral solution launch remains uncertain. In Hatch-Waxman contexts, stays can last 12–18 months pending PTAB outcomes. Competing generic filers watching this case should monitor any IPR petition filings against Azurity’s seven patents, as a PTAB institution decision would materially shift the validity landscape for the entire FIRVANQ® patent portfolio.
Generic launch timing uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US11638692B2 and 6 related FIRVANQ® patentsSearch in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking U.S. market entry for vancomycin HCl oral solutionSearch in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Kaan Ekiner | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Cozen O’connor PC | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The case termination record reflects a procedural consent stay rather than a substantive verdict. Plaintiff’s counsel transmitted a proposed Consent Order Staying Proceedings to both the district judge and magistrate judge — indicating the stay was jointly negotiated. No liability, validity, or damages findings were made. The phrasing ‘consent order’ confirms mutual agreement, which typically suggests either a pending PTAB proceeding, active settlement negotiations, or a strategic agreement to defer merits adjudication pending an external trigger.
US11638692B2 — FIRVANQ® vancomycin hydrochloride oral solution formulations
The seven asserted patents cover vancomycin hydrochloride oral solution formulations marketed by Azurity as FIRVANQ®, an antibiotic used to treat Clostridioides difficile-associated diarrhea and enterocolitis. The portfolio spans application dates from approximately 2015 (US15/126059, underlying US10959946B2) through to 2022 (US17/965253, underlying US11638692B2), suggesting formulation improvements, stability enhancements, or method-of-use refinements were added progressively to extend the patent estate.
For the specialty pharmaceutical sector, a seven-patent portfolio around a single liquid antibiotic product represents a robust defensive moat. Vancomycin HCl oral solution has limited branded competition, making FIRVANQ® a commercially significant asset. Any generic entrant — including Annora Pharma — must either design around all seven patents, successfully invalidate each through IPR, or negotiate a licensing settlement. The staggered application dates make clearance analysis complex and increase the litigation cost for challengers.
Should your team run an FTO analysis against the FIRVANQ® patent portfolio?
Any company developing, manufacturing, or seeking FDA approval for a generic vancomycin hydrochloride oral solution product in the United States should conduct a freedom-to-operate analysis against all seven patents asserted in this case. The portfolio’s breadth — spanning multiple application years and likely covering formulation composition, manufacturing methods, and stability profiles — means that a single FTO assessment may be insufficient without claim-level analysis across all seven grants.
PatSnap Eureka’s FTO Search Agent can map each of the seven asserted patents against your product specifications, flag overlapping claim elements, and identify prior art that may support validity challenges. For ANDA filers, Eureka can also track PTAB petition status across the FIRVANQ® patent family in real time — enabling counsel to align IPR filing strategy with district court stay timing for maximum procedural efficiency.
Run a freedom-to-operate analysis on US11638692B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA vancomycin and oral antibiotic patent cases in U.S. district courts
Explore related Hatch-Waxman infringement actions involving oral antibiotic formulation patents litigated in the District of New Jersey and comparable ANDA venues.
What this stay signals for the branded oral solution IP landscape
A seven-patent consent stay in ANDA litigation rarely happens without a strategic catalyst — here is what practitioners should watch.
Seven-patent portfolios create layered IPR exposure for generic challengers
Azurity’s assertion of seven patents covering FIRVANQ® reflects a common branded pharma strategy: layering formulation, method-of-use, and manufacturing patents to create multiple validity challenges for generics. Each patent represents a separate IPR filing opportunity for Annora — but also seven separate validity hurdles to clear before launching. IP teams should audit each patent’s prosecution history for potential weaknesses.
Consent stays are a strong signal of parallel PTAB activity or settlement
When both parties agree to stay ANDA district court litigation within 188 days of filing, the most common triggers are: (1) one or more IPR petitions filed by the defendant, (2) active settlement negotiations, or (3) both simultaneously. Monitoring PTAB dockets for IPR petitions against US11638692B2 and the six co-asserted patents will reveal whether validity challenges are driving the hold.
Azurity v Annora — key questions answered
Azurity asserted seven U.S. patents: US11638692B2, US10959947B2, US10959949B2, US10493028B2, US10959946B2, US10959948B2, and US10688046B2. All seven relate to FIRVANQ® vancomycin hydrochloride oral solution formulations used to treat Clostridioides difficile infections.
The case was stayed by a consent order — meaning both parties jointly agreed to pause proceedings and the court accepted. A stay does not dismiss the case or resolve any merits. It suspends all district court activity while external processes — most likely PTAB IPR proceedings or settlement negotiations — proceed. The case can resume if either party moves to lift the stay.
The public record designates this as a patent infringement action, consistent with Hatch-Waxman ANDA litigation. Annora Pharma is an Indian generic pharmaceutical manufacturer, and the product at issue — vancomycin hydrochloride oral solution — is a branded prescription drug. The procedural pattern, including the early consent stay, is characteristic of ANDA patent litigation.
FIRVANQ® is Azurity Pharmaceuticals’ branded vancomycin hydrochloride oral solution approved to treat Clostridioides difficile infections. Its patent portfolio comprises at least seven U.S. patents with application dates spanning 2015 to 2022. This staggered portfolio structure is designed to extend market exclusivity and creates multiple validity challenges — and potentially multiple IPR petitions — for any generic entrant seeking FDA approval.
The case is before the U.S. District Court for the District of New Jersey (Case No. 2:24-cv-08809). The Honorable Susan D. Wigenton serves as the district judge and the Honorable Jose R. Almonte serves as the magistrate judge. Plaintiff is represented by Saiber LLC (Arnold B. Calmann and Katherine Ann Escanlar) and defendant by Cozen O’Connor PC (Kaan Ekiner).
PatSnap Eureka searches patents and litigation data to answer instantly.